dabrafenib  (MedChemExpress)

Journal: Nature Communications

Article Title: Supporting cells orchestrate noise-induced hearing loss via a Gasdermin D-dependent signaling loop with hair cells

doi: 10.1038/s41467-025-66152-6

Figure Lengend Snippet: a Comparison of GSDMD changes between WT and Tlr4 KO mice following noise exposure, evaluated at 8 h-PNE. Detection parameters included short exposure (5 s) and prolonged exposure (30 s) to visualize GSDMD-FL and GSDMD-N bands, respectively. b , c Effect of Zorifertinib (EGFR inhibitor) on GSDMD, 4HNE, p-ERK, and t-ERK levels in WT mice after NE, evaluated at 8 h-PNE. d Representative confocal and 3D images of p-ERK (green) in cochlear tissues before and immediately after noise exposure. e – g Effect of Dabrafenib (an inhibitor to reduce p-ERK levels) on GSDMD, 4HNE, p-ERK, and t-ERK levels in WT mice after NE, evaluated at 8 h-PNE. h Representative WB analysis of p-ERK and t-ERK in cochlea transfected with/without AAV-HC- Gpx4 . The p-ERK/t-ERK ratios were normalized to β-actin as a loading control and presented as fold-changes relative to the vehicle group (set to 1). i Immunolabeling of p-ERK (green) in the 22.6–32 kHz cochlear region in non-AAV and AAV-HC- Gpx4 -transfected mice with noise exposure, observed at 0 h-PNE. A significant reduction in p-ERK activation was observed in the OHC region of Gpx4 -transfected mice. All data are presented as mean ± SEM ( n = 3 biological replicates). Statistical analysis was performed using one-way ANOVA with Bonferroni post hoc test. ns, not significant. Scale bar = 10 μm. WT wild type, NE noise exposure, Zori Zorifertinib, Dab Dabrafenib, SCs supporting cells, OHC outer hair cells, IHC inner hair cells, PC pillar cells, DC Deiter cells, p-ERK phosphorylated ERK, t-ERK total ERK.

Article Snippet: Zorifertinib (HY-18750), Dabrafenib mesylate (HY-14660) and ASN007 (HY-136579A) were purchased from MedChemExpress.

Techniques: Comparison, Transfection, Control, Immunolabeling, Activation Assay

Journal: Biochemistry and Biophysics Reports

Article Title: OT17 a novel microsatellite stable colorectal cancer cell line and organoid model for investigating BRAF V600E mutant tumorigenesis and targeted therapeutics

doi: 10.1016/j.bbrep.2025.102235

Figure Lengend Snippet: Drug sensitivity analysis of three organoid lines. (a–c) Representative photomicrographs of the three organoid lines. (d–f) Each organoid line was treated with seven escalating drug concentrations (0.27–200 μM, three-fold concentration increments) plus a vehicle control that received an equal volume of low-dose DMSO (≤0.1 %) as carrier. Organoids were plated, cultured for ∼4 days, and dosed once their mean diameter exceeded 50 μm. After a further 4-day exposure, luminescence was measured with the CellTiter-Glo assay and converted to percent viability. Viability values were normalized to the vehicle control, and dose–response curves were fitted with a four-parameter logistic model to calculate IC 50 values (mean ± SD, n = 3 wells). (g) CO17 organoids were treated with gradient concentrations of dabrafenib (maximum 200 μM, threefold serial dilutions) with or without 140 μg/mL cetuximab for four days. Organoid viability was assessed using the CellTiter-Glo (CTG) assay, and IC 50 curves were plotted. (mean ± SD, n = 3 wells).

Article Snippet: After waiting for 3–4 days, when the organoids reach approximately 50 μm in size, add the drugs Dabrafenib (MCE, HY-14660) and Trametinib (MCE, HY-10999).

Techniques: Concentration Assay, Control, Cell Culture, Glo Assay, CTG Assay